Loading company…
Vancouver-based Sonic Incytes develops the VELACUR system, an AI-guided ultrasound device for assessing liver health.
Founded in 2017 and based in Vancouver, Canada, Sonic Incytes Medical Corp. develops diagnostic tools for liver health. Its VELACUR system is an AI-guided 3D S-WAVE ultrasound elastography device that measures liver stiffness and Velacur Determined Fat Fraction for fatty liver disease, and it is sold directly to hospitals and clinics. The company was founded by Robert Rohling and Tim Salcudean, and CEO Barry Allen leads it. On December 7, 2021 it raised USD 7.3 million in Series A funding led by Nimbus Synergies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in